Effect of tixagevimab/cilgavimab for pre-exposure prophylaxis during the China Omicron outbreak
出版年份 2023 全文链接
标题
Effect of tixagevimab/cilgavimab for pre-exposure prophylaxis during the China Omicron outbreak
作者
关键词
-
出版物
Expert Review of Anti-Infective Therapy
Volume -, Issue -, Pages 1-7
出版商
Informa UK Limited
发表日期
2023-10-19
DOI
10.1080/14787210.2023.2272866
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Estimating the transmission dynamics of SARS-CoV-2 Omicron BF.7 in Beijing after adjustment of the zero-COVID policy in November–December 2022
- (2023) Kathy Leung et al. NATURE MEDICINE
- Tixagevimab/Cilgavimab in SARS-CoV-2 Prophylaxis and Therapy: A Comprehensive Review of Clinical Experience
- (2023) Karolina Akinosoglou et al. Viruses-Basel
- Tixagevimab/cilgavimab for preventing COVID-19 during the Omicron surge: retrospective analysis of National Veterans Health Administration electronic data
- (2023) Yinong Young-Xu et al. mBio
- Omicron variant escapes therapeutic mAbs including recently released Evusheld ®, contrary to eight prior main VOC
- (2022) Céline Boschi et al. CLINICAL INFECTIOUS DISEASES
- Frailty and mortality associations in patients with COVID ‐19: A Systematic Review and Meta‐analysis
- (2022) Ashwin Subramaniam et al. INTERNAL MEDICINE JOURNAL
- Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2
- (2022) Lihong Liu et al. NATURE
- Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies
- (2022) Robert Stuver et al. CANCER CELL
- Effectiveness of Paxlovid in Reducing Severe COVID-19 and Mortality in High Risk Patients
- (2022) Ronza Najjar-Debbiny et al. CLINICAL INFECTIOUS DISEASES
- Pre-exposure prophylaxis with 300 mg Evusheld elicits limited neutralizing activity against the Omicron variant
- (2022) Ilies Benotmane et al. KIDNEY INTERNATIONAL
- Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies
- (2022) Timothée Bruel et al. NATURE MEDICINE
- Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19
- (2022) Myron J. Levin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis
- (2022) Ainsley Ryan Yan Bin Lee et al. BMJ-British Medical Journal
- Association between AZD7442 (tixagevimab-cilgavimab) administration and SARS-CoV-2 infection, hospitalization and mortality
- (2022) Jennifer Kertes et al. CLINICAL INFECTIOUS DISEASES
- Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld©) for COVID-19 among 1112 severely immunocompromised patients
- (2022) Yann Nguyen et al. CLINICAL MICROBIOLOGY AND INFECTION
- Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5
- (2022) Nicole P. Hachmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tixagevimab and Cilgavimab (Evusheld) boosts antibody levels to SARS-CoV-2 in patients with multiple sclerosis on b-cell depleters
- (2022) William L. Conte et al. Multiple Sclerosis and Related Disorders
- Characterization of Early-Onset Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients Who Received Tixagevimab-Cilgavimab Prophylaxis
- (2022) Eloy E Ordaya et al. Open Forum Infectious Diseases
- Real-World Evidence of Neutralizing Monoclonal Antibodies for Preventing Hospitalization and Mortality in COVID-19 Outpatients
- (2022) Matthew K. Wynia et al. CHEST
- Real-World Experience of Tixagevimab and Cilgavimab (Evusheld) in Rheumatologic Patients on Rituximab
- (2022) Anthony J. Ocon et al. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY
- Association Between Immune Dysfunction and COVID-19 Breakthrough Infection After SARS-CoV-2 Vaccination in the US
- (2021) Jing Sun et al. JAMA Internal Medicine
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started